SCHEMBL167425

SCHEMBL167425

CCCn1ccc(C(=O)O)n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.49
PLA2G4A P47712 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.44
KDM4C Q9H3R0 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 7/20 0.40
NPC1 O15118 6/20 0.40
MEN1 O00255 1/20 0.39
PTGER1 P34995 1/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17288867 0.89 PLA2G4A (0.50) SMN1; SMN2PLA2G4AL3MBTL1ALDH1A1KMT2A
SCHEMBL27793505 0.88 PLA2G4A (0.52) SMN1; SMN2PLA2G4AL3MBTL1ALDH1A1KMT2A
SCHEMBL11365598 0.86 PLA2G4A (0.54) SMN1; SMN2PLA2G4AL3MBTL1ALDH1A1KMT2A
SCHEMBL932824 0.85 ALDH1A1 (0.55) SMN1; SMN2PLA2G4AALDH1A1KMT2AKDM4C
SCHEMBL2361631 0.84 ALDH1A1 (0.44) SMN1; SMN2L3MBTL1ALDH1A1KMT2AKDM4C
SCHEMBL15202347 0.83 SMN1; SMN2 (0.50) SMN1; SMN2PLA2G4AALDH1A1KMT2AKDM4C
SCHEMBL25786633 0.82 RAB9A (0.57) SMN1; SMN2ALDH1A1KMT2AKDM4CCYP1A2
SCHEMBL14531457 0.82 SMN1; SMN2 (0.47) SMN1; SMN2PLA2G4AALDH1A1KMT2AKDM4C
SCHEMBL1431755 0.81 SMN1; SMN2 (0.49) SMN1; SMN2PLA2G4AALDH1A1KMT2AKDM4C
SCHEMBL948098 0.81 CYP1A2 (0.50) ALDH1A1KMT2ACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed
EP-2609091-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS Lead Discovery Center GmbH (DE) 2013-07-03 EP disclosed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 WO disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 EP disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 SMN1; SMN2 3453/4885PLA2G4A 2932/4885L3MBTL1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.